Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG; Boucher Y; di Tomaso E; Duda DG; Munn LL; Tong RT; Chung DC; Sahani DV; Kalva SP; Kozin SV; Mino M; Cohen KS; Scadden DT; Hartford AC; Fischman AJ; Clark JW; Ryan DP; Zhu AX; Blaszkowsky LS; Chen HX; Shellito PC; Lauwers GY; Jain RK; Nature Medicine, 2004, vol. 10, issue 2, p 145, ISSN 10788956. ISBN 10788956.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef